SOPHiA GENETICS SA (NASDAQ:SOPH) Q4 2022 Results Earnings Conference Call March 7, 2023 8:00 AM ET

Company Participants

Katherine Bailon - Vice President, Investor Relations

Jurgi Camblong - Founder and Chief Executive Officer

Ross Muken - Senior Vice President and Chief Financial Officer

Conference Call Participants

Tejas Savant - Morgan Stanley

Richard Hilliker, Jr. - Credit Suisse

Mark Massaro - BTIG

Marta Nazarovets - J.P. Morgan

Operator

Good morning and welcome to SOPHiA GENETICS' Fourth Quarter Fiscal 2022 Earnings Call. All participants will be in listen-only mode. [Operator Instructions]. Please note this event is being recorded.

I would now like to turn the conference over to Katherine Bailon, Head of Investor Relations at SOPHiA GENETICS. Please go ahead.

Katherine Bailon

Good morning and thank you for joining us on SOPHiA GENETICS Q4 fiscal 2022 earnings call. My name is Katherine Bailon, and I am Head of Investor Relations at SOPHiA GENETICS.

Joining me today are Dr. Jurgi Camblong, our Co-Founder and Chief Executive Officer, and Ross Muken, our Chief Financial Officer.

Before we get started, I'd like to remind you that the management team will make statements during this call that are forward looking, within the meaning of US federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties appear in the section entitled Cautionary Statement Regarding Forward-Looking Statements in Form 20-F on file with the SEC. Except as required by law, SOPHiA GENETICS disclaims any intention or obligation to update or revise any financial or product pipeline projections or other forward-looking statements, whether because of new information, future events, or otherwise.

This conference call contains time sensitive information and is accurate only as of its broadcast March 7, 2023.

This presentation includes non-IFRS financial measures. These measures are calculated by management and do not have any standardized meaning under IFRS. These non-IFRS measures supplement IFRS measures, but should not be viewed as substitutes for IFRS measures. We have included a reconciliation of IFRS measures to non-IFRS measures in our press release issued this morning, which is available on our website.

Please note both a replay of this call and the earnings release will be available on our website in the Investors section.

And with that, I'll now turn it over to Jurgi.

Jurgi Camblong

Thank you, Katherine. And good morning, everyone. 2022 was a tremendous year for SOPHiA GENETICS, and I am pleased to share with you today the momentum that we built in the period, including a strong finish to our fourth quarter.